Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
about
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinModeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.Disease Progression Modeling: Key Concepts and Recent DevelopmentsMathematical modeling of efficacy and safety for anticancer drugs clinical development.
P2860
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@ast
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@en
type
label
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@ast
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@en
prefLabel
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@ast
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@en
P2093
P2860
P356
P1476
Disease Progression/Clinical O ...... Patients Treated With Eribulin
@en
P2093
A D R Huitema
J H Beijnen
J H M Schellens
P2860
P304
P356
10.1002/PSP4.49
P577
2015-06-30T00:00:00Z